Immuneering (NASDAQ:IMRX) Now Covered by HC Wainwright

Key Points

• HC Wainwright initiated coverage of Immuneering with a Buy rating and a $14 price target, implying 218.91% upside from the stock’s previous close.
• Analyst sentiment is generally positive: Immuneering has a consensus Buy rating and an average price target of $18, though two firms maintain Sell ratings.
• Shares opened at $4.39, while the company recently reported a quarterly loss of $0.27 per share, narrowly missing estimates; institutional investors own 67.65% of the stock.

Analysts at HC Wainwright began coverage on shares of Immuneering (NASDAQ:IMRX - Get Free Report) in a research report issued to clients and investors on Thursday, MarketBeat reports. The brokerage set a "buy" rating and a $14.00 price target on the stock. HC Wainwright's price target suggests a potential upside of 218.91% from the stock's previous close.

A number of other brokerages have also issued reports on IMRX. Needham & Company LLC raised their target price on Immuneering from $11.00 to $18.00 and gave the stock a "buy" rating in a research note on Monday, July 20th. Oppenheimer reiterated an "outperform" rating on shares of Immuneering in a research note on Monday, June 1st. Wall Street Zen lowered Immuneering from a "hold" rating to a "sell" rating in a report on Monday, July 20th. Cantor Fitzgerald started coverage on Immuneering in a research note on Wednesday, July 8th. They issued an "overweight" rating and a $17.00 price objective for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immuneering in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Immuneering presently has a consensus rating of "Buy" and an average price target of $18.00.

Immuneering Stock Performance

Shares of NASDAQ IMRX opened at $4.39 on Thursday. The business has a 50-day simple moving average of $4.60 and a two-hundred day simple moving average of $4.98. The company has a market cap of $284.03 million, a PE ratio of -3.75 and a beta of 0.43. Immuneering has a fifty-two week low of $2.90 and a fifty-two week high of $10.08.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.01). The business had revenue of $0.36 million for the quarter. On average, sell-side analysts predict that Immuneering will post -1.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immuneering

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMRX. Caitong International Asset Management Co. Ltd purchased a new position in shares of Immuneering during the 4th quarter valued at approximately $33,000. Levin Capital Strategies L.P. acquired a new position in shares of Immuneering in the 1st quarter valued at $53,000. Mercer Global Advisors Inc. ADV purchased a new stake in Immuneering during the third quarter worth $70,000. SummitTX Capital L.P. purchased a new stake in Immuneering during the fourth quarter worth $69,000. Finally, Ausdal Financial Partners Inc. acquired a new stake in Immuneering during the fourth quarter valued at $72,000. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source